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Immuno affinity chromatography with virus neutralizing monoclonal antibodies. directed to the hae- 
magglutinating protein of canine parvovirus (CPV) was used to purify and concentrate CPV from in- 
fected cell culture. The procedure was monitored by testing the respective fractions in an infectivity 
titration system. in an ELISA. in a haemagglutination assay and by negative contrast electron micros- 
copy to quantify CPV or CPV antigen. The degree of purification was further estimated by testing the 
fractions for total protein content in a calorimetric method, for bovine serum albumin content in an 
ELISA and by SDS-PAGE. Over 99% of the contaminating proteins proved to be removed. and 2O?i 
or 70-90% of infectious CPV or CPV antigen. respectively, was recovered. 
Canine parvovirus: Purification; Immuno affinity chromatography; Monoclonal antibody 
Introduction 
Canine parvovirus (CPV) is a nonenveloped single-stranded DNA virus that may 
cause an occasionally fatal enteritis-panleukopenia syndrome in dogs (Appel et al.. 
1979; Gagnon and Povey. 1979; Johnson and Spradbrow, 1979; Osterhaus et al., 
1980). Purified CPV derived from culture supernatant of CPV-infected cells has 
been used for biochemical (Paradiso. 1982; Rhode, 1985), ultrastructural (Parad- 
iso, 1982), immunological (Parrish et al., 1982; Burtonboy et al., 1982; Parrish and 
Carmichael, 1983) and serological (Fiscus et al., 1985) studies. Conventional 
methods used for the purification of parvoviruses from cell culture supernatant. 
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including CaCl, precipitation (Tattersall et al., 1976), polyethylene glycol precip- 
itation (Paradiso, 1981), banding in isopycnic CsCl gradients (Tattersall et al., 1976; 
Paradiso, 1981; Parrish et al., 1982) and haemadsorption elution (Osterhaus et al., 
1980; Burtonboy et al., 1982), are multi-step and time-consuming procedures which 
are difficult to apply to large-scale purification. Immuno affinity chromatography 
(IAC) using monoclonal antibodies (MoAbs) has been shown to be a suitable 
method for the purification of viruses or viral antigens (Chong et al., 1985; Disco 
et al., 1986). Virus purification from tissues infected with Aleutian mink disease 
virus, a member of the Parvoviridae family, by IAC using a polyclonal antibody 
preparation has been described (Kenyon et al., 1973). 
In the present study, we describe the purification and concentration of CPV by 
IAC using mouse MoAbs directed against the haemagglutinating (H) protein of 
CPV, immobilized to Sepharose. The method proved efficient and relatively sim- 
ple to concentrate and purify CPV from infected cell culture. 
Materials and Methods 
Virus 
The continuous canine cell line A-72 (Binn et al., 1980) was cultivated in Ea- 
gle’s medium supplemented with Hanks’ salts, lactalbumine hydrolysate (5.13 g/l), 
natriumcarbonate 350 mg/l, glutamine 0.002 M, 100 IU penicillin/ml, 100 pg 
streptomycin/ml, and 10% fetal calf serum in 850 cm2 roller bottles (Costar) roll- 
ing at 0.4 rpm at 37°C. Complete monolayers were trypsinized, washed and re- 
suspended in phosphate-buffered saline (PBS) (pH 7.4). 
The resuspended cells (10’ per ml) were infected with CPV (strain C780916; 
Carmichael et al., 1981) at a m.o.i. of about 10-j TCID,, per cell, by incubating 
the cells with CPV in a rolling bottle for 90 min at 37°C. After low speed centrif- 
ugation, the cells were resuspended in culture medium and cultivated at 37°C in 
roller bottles. Four to five days postinfection, the cultures exhibiting cytopathic 
changes were frozen and thawed twice. The suspension was clarified by centrifu- 
gation for 15 min at 2000 x g and used as starting material for IAC. 
Production and characterization of MoAbs 
A panel of hybridomas producing MoAbs reactive with the H protein of CPV 
was generated essentially as previously described for the generation of MoAbs 
against poliovirus (Osterhaus et al., 1981). Briefly, spleen cells from BALB/c mice 
immunized with CPV were fused with a mouse myeloma cell line. Hybridomas 
producing MoAbs, positive in haemagglutination inhibition (HI) and virus neu- 
tralization (VN) tests (see below), were selected and single cell cloned twice. Mouse 
ascitic fluids were produced in BALBic mice. Ig was isolated from mouse ascitic 
fluids by precipitation with ammonium sulphate and affinity chromatography using 
Protein A-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) (SeppG et 
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al., 1981; Manil et al., 1986). Purified antibodies were conjugated to horseraddish 
peroxidase (HRP) according to standard methods (Nakane and Kawaoi, 1974). 
The epitope specificity of the MoAbs was determined in a competition ELISA 
system on CPV-coated microtiter plates (Titertek, Flow Laboratories). For this 
ELISA, CPV was coated in an optimal dilution in 0.1 M sodium carbonate buffer 
(pH 9.6). After washing with demineralized water containing 0.05% Tween 80 
(Merck, Schuchardt, F.R.G.) (DWT), 100-~1 volumes of lo-fold dilutions of un- 
conjugated antibodies (ascitic fluids) were made in PBS containing 1% bovine 
serum albumin (BSA) (Organon Techika, Oss, The Netherlands) and 0.05% Tween 
80 and incubated for 30 min at room temperature. The plates were washed with 
DWT and homologous or heterologous HRP-conjugated MoAbs were added at 
the appropriate dilutions and incubated for 30 min. The plates were washed twice 
and 100 ~1 of substrate solution (0.1 mgiml tetramethylbenzidine [TMB]) and 
0.003% H,Oz in 0.1 M NaAc buffer (pH 5.5) was added to each well. After 10 min 
at room temperature, 100 ~1 of 2 M HzSO, was added to stop the reaction. The 
absorbance at 450 nm was read in a Titertek Multiskan (Titertek, Flow Labora- 
tories). 
Isotypes of the MoAbs were determined in an ELISA system. For this ELISA, 
Protein A-purified anti-CPV MoAbs were diluted in PBS containing 1% BSA 
(Organon Technika) and 0.05% Tween 80 (Merck) and incubated for 30 min in 
wells of CPV-coated microtiter plates (Titertek, Flow Laboratories). After wash- 
ing, 100 ~1 of rabbit anti-mouse antibody preparations, specific IgGl, IgG2a, IgG2b, 
IgG3, IGM or IgA (Litton Bionetics, Charleston, U.S.A.), were added in 1:lOOO 
dilutions and incubated for another 30 min. After washing, 100 ~1 swine anti-rab- 
bit HRP-conjugated antibody (Dakopatts, Denmark) was added in a 1:lOOO di- 
lution and incubated for 30 min. The plates were washed and developed with TMB 
substrate as described above. 
IAC chromatography 
Protein A-Sepharose IAC-purified MoAbs were dialysed against coupling buffer 
and coupled to CNBr-activated Sepharose 4-B (20 mg McAb to 10 ml gel volume) 
as recommended by the manufacturer (Pharmacia Fine Chemicals). The column 
was equilibrated with TEN buffer (20 mM Tris, 1 mM EDTA, 0.15 M NaCl ad- 
justed to pH 7.8 with HCI). To 90 ml of clarified culture supernatant from CPV- 
infected cells 10 ml of a 10 times concentrated TEN buffer was added together with 
solid NaCl to a final concentration of 0.65 M NaCl. 
CPV was allowed to bind overnight by running the column at low speed 
(20 ml/h). After washing the column with 20-30 ml TEN buffer supplemented with 
0.5 M NaCl, the virus was eluted with TEN buffer containing 3 M NH,SCN and 
dialysed against PBS. All steps were carried out at 4°C. 
Effluent (unbound material) and eluate fractions were tested in SDS-PAGE and 
in the respective biological assays (see below). Protein concentrations were deter- 
mined by the calorimetric method of Bradford (Bradford, 1976) adapted to a mi- 
crotiter system. 
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Double antibody sandwich ELISA 
For the detection and quantification of CPV antigen, a double antibody sand- 
wich ELISA was used. Microtiter plates were coated with two Protein A-purified 
MoAbs (H-l and H-2) which recognize two different epitopes (see below), 100-~1 
volumes containing 250 ng of each MoAb were incubated in microtiter plates for 
16 h at 4°C. After washing with DWT, 150-~1 volumes of a 1% BSA solution con- 
taining 0.1% NaN, in distilled water were added. The plates were sealed and stored 
at 4°C until use. 
Plates were washed with DWT and 50-~1 volumes of 3-fold serial dilutions of 
CPV suspensions were added simultaneously with 50 ~1 of HRP-conjugated MoAbs 
H-l and H-2. After incubation for 30 min at 37”C, the plates were washed twice 
and developed with TMB substrate. 
HA and HI tests 
HA and HI tests were performed in 96-well round bottom microtiter plates as 
described (Appel et al., 1979; Carmichael et al., 1980; Osterhaus et al., 1980a), 
using African green monkeys (Cercopithecus aethiops) erythrocytes. 
Infectivity and VN tests 
For infectivity titrations, 1.8-ml volumes of lo-fold dilutions of CPV prepara- 
tions in PBS were mixed with 0.9-ml volumes of a suspension containing 8 x 10” 
A-72 cells per ml in PBS. The mixtures were incubated for 90 min at 37°C and 
gently agitated every 15 min. Cells were pelleted by low speed centrifugation, re- 
suspended in 5.4-ml culture medium and divided over eight Lab Tek chambers 
(Miles, Napperville, U.S.A.). After 4 days of cultivation at 37”C, cells were fixed 
with ethanol at -70°C and examined by immuno fluorescence using one of the 
Protein A-purified anti-CPV MoAb and a FITC-conjugated swine anti-mouse 
preparation (Nordic, Tilburg, The Netherlands). For VN tests, the same proce- 
dure was followed: after incubation for 1 h at 20°C of 100 TCIDS,, CPV with di- 
lutions of the respective MoAbs. 
Electron microscopy 
For negative contrast examination, small drops of the samples to be tested were 
placed on formvaricarbon-coated grids and contrasted with 2% phosphotungstic 
acid (adjusted to pH 2.5 with KOH). The preparations were examined in a Philips 
EM 400T transmission electron microscope. 
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BSA-ELISA 
Cell culture harvests and column fractions were tested for BSA content in an 
ELISA using an anti-BSA mouse MoAb (IgGl) coupled to HRP (Avest and Os- 
terhaus, submitted for publication). In short, samples were coated to microtiter 
plates in serial lo-fold dilutions in sodium carbonate buffer (pH 9.6) for 2 h at 37°C. 
After washing, 100 ~1 of a 1:3000 dilution of the anti-BSA conjugate in PBS con- 
taining 0.05% Tween and 0.25% ovalbumine (Sigma Chemical, St. Louis, MO). 
Plates were washed and developed with TMB as described above. For the deter- 
mination of BSA content, ELISA values were compared with those obtained with 
standard dilutions of a BSA (Boseral, Organon, Oss, The Netherlands) prepara- 
tion. 
SDS-PAGE 
Proteins were analysed on 12% polyacrylamide slab gels (Laemmli, 1970). Gels 
were silverstained (Wray et al., 1981). Proteins of known molecular weights (Bio- 
Rad, Richmond, U.S.A.) were included to estimate the molecular weights of viral 
proteins. 
Results 
MoA bs 
A panel of four stable hybridomas producing HI-positive VN MoAbs (H-l, H- 
2, H-3 and H-4) were selected. These MoAbs also reacted with the haemagglu- 
tinin of feline panleukopenia virus (FPV) and recognized at least two different ep- 
itopes as was demonstrated in the competition ELISA (Table 1). The isotypes of 
the four MoAbs proved to be IgG2a, IgG2b, IgGl and IgG2b, respectively (Table 
1). MoAbs H-l and H-2 were used in further IAC purification studies. 
IAC 
Two small Sepharose 4-B columns (bed volume 1.0 ml) were prepared with 
MoAbs H-l and H-2, respectively, which were shown to recognise different epi- 
topes (Table 1). When 10 ml of CPV-infected culture material (HA titer 1024; 
double antibody sandwich ELISA titer 30) were passed through either of the col- 
umns, no infectious CPV or CPV antigen (ELISA/HA) could be detected in the 
effluent material of the columns. Upon elution with 3 M NH,SCN, CPV antigen 
could be eluted from both columns with about the same efficiency, as judged from 
ELISA and HA titrations carried out with the respective fractions collected from 
both columns. The profiles obtained in HA and ELISA coincided well with those 
obtained with the lo-ml bed volume column described below (not shown). To in- 
vestigate further the potential of the IAC procedure for the purification and con- 
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TABLE 1 
Properties of anti-CPV MoAbs. 
MoAb Log” titer in competition ELISA 
HRP-conjugate 
isotvue 
H-l 
H-2 
H-3 
H-4 
H-l H-2 
2 _* 
_ 4 
_ _ 
4 _ 
H-3 
2 
_ 
4 
4 
H-4 
2 
- 
2 
4 
IgG2a 
IgG2b 
IgGl 
IrG2b 
*--:c 1. 
centration of CPV from cell culture material, a 10-m] bed volume affinity column 
was prepared with MoAb H-l. When 100 ml of the CPV-infected culture material 
were passed through this column again, neither CPV nor CPV antigen could be 
detected by HA, ELISA or infectivity assays in the effluent (Fig. l), and no or 
only few irregular parvovirus-like particles were observed by negative contrast 
electron microscopy (Fig. 2). The effluent contained relatively high concentrations 
of contaminating proteins (up to about 4 mg/ml) including BSA as was also visu- 
alized by SDS-PAGE in the initial effluent fractions (Fig. 3). which gradually de- 
HA hter 
- 
8192- 
ELISA titer 
,qprotein/ml 
w - 
Loo0 
I 
Bl- 1000 
16- 
9- 
,ug BSA/ml 
- 
\ _ 
+ I 
1 5 lo '~RA,T,,N2~",BER 25 3o 35 
I 
Fig. 1. Purification of CPV by IAC. Arrow indicates change of buffers. Fractions were collected and 
monitored for ELISA reactivity (O-O), haemagglutination activity (O-O). protein content, (O-O), 
BSA content, (m-m) and infectivity (A-A). 
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Fraction number 4 Fraction number 30 
Fig. 2. Analysis of eftluent and eluate fractions by electron microscopy. (123.000 X) 
100 nm. 
Bar represents 
clined upon washing the column with the starting buffer (Fig. 1). CPV and/or CPV 
antigen could be readily recovered from the column by elution with 3 M NH,SCN, 
as was shown by titration in infectivity assays, HA, and ELISA of the eluate frac- 
tions (Fig. 1, Table 2). On the basis of the titers found in the respective assays, it 
was concluded that a recovery of about 20% of infectious CPV, and of about 
70-90% of CPV antigen could be achieved, and that maximal concentration ef- 
fects of about four and 16 times, respectively, were obtained. Analysis of eluate 
fractions by negative contrast electron microscopy confirmed the presence of large 
numbers of predominantly full virus particles, apparently free from contaminating 
membranous structures, in the fractions with the highest CPV and CPV antigen 
concentrations (Fig. 2). Total protein and BSA concentrations in these peak frac- 
tions measured about 40 and 8 kg/ml, respectively. In eluate peak fractions, only 
three protein bands could be visualized by SDS-PAGE at molecular weights cor- 
responding to those of parvovirus proteins: 82.5.10’, 67.5.10’ and 65.10”, respec- 
tively (Fig. 3). 
The column could be used more than 20 times without apparent loss its of bind- 
ing capacity. This capacity proved at least three times higher than the amount of 
antigen used in the experiments mentioned above. 
Discussion 
In the present paper, we show that IAC, using a MoAb directed against the H 
protein of CPV, provides a rapid and relatively simple procedure for the purifi- 
cation and concentration of CPV from cell culture material. Analysis of the frac- 
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Fraction number Fraction number 
Fig. 3. Analysis of effluent (A) and eluate (B ) fractions by SDS-PAGE. Gels were silverstained by 
the method of Wray et al. (1981). Marker proteins were used to estimate molecular weights (MW) of 
viral proteins (MW in Da x 1V’). 
tions by HA, ELISA, SDS-PAGE, and negative contrast electron microscopy in- 
dicated the efficiency with which CPV could be purified and concentrated using 
this method. The possible discrepancy observed between the results obtained with 
effluent fraction by EM on the one hand and ELBA or HA on the other hand 
may be explained by the relatively high cutoff values chosen (five times back- 
ground), and the relative insensitivity of the test, respectively. The possible dis- 
crepancy between infectivity and EM results may be explained by the fact that at 
most only noninfectious or damaged virus particles were present in the effluent. 
The recovery of CPV antigen, as judged from HA and ELISA titrations was 
7@-!%I%, whereas the recovery of infectious CPV. as shown by infectivity titra- 
tions, proved to be about 20%. The loss of infectivity probably is a direct effect 
of the elution conditions used and the procedure of dialysis, followed by freezing 
and thawing before testing. This was confirmed by testing of CPV culture material 
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TABLE 2 
Quantitative data of IAC purification and concentration procedure 
Culture 
supernatant 
Effluent 
fractions 
Volume net (ml) 90 1.8 
Protein concentration (&ml) 3825 ~15 - 3925 
BSA concentration (pgiml) 3000 2.6 - 3900 
HA titer 1024 0 
ELISA titer 30 
Infectivity (log,,, TCID,,,lml) 4.9 
EM +** 
Eluate 
fractions 
0 
<I 
I.8 
<IS - 40 
0.15 - 8 
0 - 16.000 
(70%)* 
0 - 730 
(90%) 
2.2 ~ 5.5 
(20%) 
++++ 
* Estimated total recovery. 
** Arbitrary units indicating the number of virus particles observed: + = small numbers; + + + + = 
large numbers (Fig. 3). 
directly treated in the same way (not shown). This reduction in infectivity might 
partly be overcome by using a procedure of NH,SCN gradient elution in combi- 
nation with gel filtration. Over 99% of the contaminating proteins were shown to 
be removed in the IAC procedure, by determination of the reduction of the BSA 
content in an ELISA, of the total protein content by calorimetry and by compar- 
ing the different fractions in SDS-PAGE. Since BSA is the major contaminating 
protein present in fetal calf serum used in our cell culture system, it may be con- 
cluded from our data that the determination of the BSA content may be consid- 
ered a proper method to validate the purification procedure. The small BSA peak 
present in the eluate fractions containing most intact CPV particles and infectivity 
may be explained by a nonspecific binding of BSA to either the affinity column or 
directly to CPV. 
The use of the IAC method described for the purification and concentration of 
CPV may not only be of interest for the production of purified CPV for biochem- 
ical, ultrastructural and immunological studies, but may also be applied to pro- 
duce infectious CPV or CPV antigen to be used for vaccination purposes or in di- 
agnostic tests. The cross-reactivity of the respective MoAbs with FPV would also 
offer the opportunity to use these for the same applications with this virus. 
A similar approach of IAC using MoAb would also be of interest for the puri- 
fication of human parvovirus B19, e.g., from viraemic plasma, since no in vitro 
cultivation systems are available for this virus at present (Siegl, 1984). 
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